Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)

被引：2
|
作者：
Burns, Ethan A. [1 ]
Ensor, Joe E. [2 ]
Anand, Kartik [3 ]
Gentille, Cesar [4 ]
Guerrero, Carlo [1 ]
Kieser, Ryan B. [1 ]
Umoru, Godsfavor [5 ]
Shah, Shilpan S. [1 ]
Petkova, Jenny H. [6 ]
Ganguly, Siddhartha [6 ,7 ]
Rice, Lawrence [8 ]
Pingali, Sai Ravi Kiran [1 ]
机构：
[1] Houston Methodist Canc Ctr, Houston, TX USA
[2] Houston Methodist Res Inst, Houston, TX USA
[3] Callahan Canc Ctr, Great Plains Hlth, North Platte, NE USA
[4] Stanford Univ, Sch Med, Div Blood & Marrow Transplantat & Cellular Therap, Stanford, CA 94305 USA
[5] Houston Methodist Hosp, Dept Pharm, Houston, TX 77030 USA
[6] Houston Methodist Hosp, Houston, TX 77030 USA
[7] Ctr Canc, Houston, TX USA
[8] Houston Methodist Hosp, Dept Med, Weill Cornell Med Collage, Houston, TX 77030 USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152068
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4740
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Daratumumab for multiple myeloma
    Croizier, Carolyne
    Bailly, Sebastien
    BULLETIN DU CANCER, 2018, 105 (11) : 985 - 991
  • [32] Therapy-associated immunosuppression and opportunistic infections in multiple myeloma patients.
    Schutt, P
    Brandhorst, D
    Stellberg, W
    Poser, M
    Ebeling, P
    Muller, S
    Buttkereit, U
    Opalka, B
    Lindemann, M
    Grosse-Wilde, H
    Seeber, S
    Moritz, T
    Nowrousian, MR
    BLOOD, 2005, 106 (11) : 367B - 367B
  • [33] Immune parameters in multiple myeloma patients:: Influence of treatment and correlation with opportunistic infections
    Schuett, Philipp
    Brandhorst, Dieter
    Stellberg, Werner
    Poser, Miriam
    Ebeling, Peter
    Mueller, Siemke
    Buttkereit, Ulrike
    Opalka, Bertram
    Lindemann, Monika
    Grosse-Wilde, Hans
    Seeber, Siegfried
    Moritz, Thomas
    Nowrousian, Mohammad R.
    LEUKEMIA & LYMPHOMA, 2006, 47 (08) : 1570 - 1582
  • [34] Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide
    Monge, Jorge
    Contreras, Jorge
    Elsoukkary, Sarah
    Guo, Jin
    Perry, Art
    Solomon, Robin S.
    Flicker, Kari
    Jayabalan, David S.
    Coleman, Morton
    Rossi, Adriana C.
    Harris, Rebecca
    Plate, Markus
    Stuebgen, Joerg-Patrick
    Niesvizky, Ruben
    BLOOD, 2019, 134
  • [35] Prevention of dental complications in patients with multiple myeloma (MM) receiving bisphosphonates treatment
    Puigmarti, C. L.
    Santos, N.
    Mostacedo, S.
    Gonzalez, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? - Literature review
    Ferreira, Luana Mota
    Cerezer, Jaderson Lima
    Gehrcke, Mailine
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2021, 43 (02) : 185 - 190
  • [37] Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM)
    Usmani, S. Z.
    Jakubowiak, A.
    Chari, A.
    Lonial, S.
    Mateos, M-V.
    Benboubker, L.
    Wu, K.
    Khokhar, N. Z.
    Wang, J.
    Doshi, P.
    Moreau, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] Successful Conversion and Implementation to Subcutaneous Daratumumab in Patients with Multiple Myeloma ( MM) and Light Chain (AL) Amyloidosis
    Hughes, David
    Henshaw, Lynnette
    Blevins, Frances
    Edwards, Camille V.
    Lerner, Adam
    Sloan, John Mark
    Sanchorawala, Vaishali
    BLOOD, 2021, 138 : 1975 - +
  • [39] Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma
    Copley, Melissa
    Metheny, Leland
    Klisovic, Rebecca B.
    Malek, Ehsan
    BLOOD, 2022, 140 : 13202 - 13203
  • [40] Nursing Implications for Patients with Relapsed and/or Refractory Multiple Myeloma Receiving Combination Therapy with Daratumumab (Darzalex™) and Lenalidomide
    Catamero, Donna
    Spencer, Patrick
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E159 - E160
12345